Skip to main content

Advertisement

Table 3 Summary of most frequent on-treatment AEs and serious AEs (safety population)

From: Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial

n, % Placebo OD PM (N = 121) FF 50 mcg OD PM (N = 121)
AEs
On treatment 46 (38) 37 (31)
On treatment, treatment-related 4 (3) 1 (<1)
On treatment, leading to withdrawal 1 (<1)a 0
Post treatment 1 (<1) 1 (<1)
Serious AEs
On treatmentb 1 (<1) 1 (<1)
On treatment AEs occurring in ≥3% patients in either treatment group
Headache 14 (12) 6 (5)
Nasopharyngitis 5 (4) 7 (6)
Pharyngitis 6 (5) 6 (5)
Influenza 4 (3) 1 (<1)
  1. aAn incidence of urticaria in one placebo-treated patient; btraffic accident, placebo group; perforated appendix, FF 50 mcg group; AE = adverse event; FF = fluticasone furoate; OD = once daily; PM = evening.